BioSpace News Archive

Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, announced an equity investment from CureDuchenne Ventures.

Siemens Healthineers announced today that its latest critical care testing solution, the RAPIDPoint® 500e Blood Gas Analyzer, has received clearance from the U.S. Food and Drug Administration.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular and neurovascular markets, announced it has closed an additional $8.8 million in Series A financing, bringing the total capital raised to date to more than $20 million.

Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the appointment of Abhinav A. Shukla, PhD, as its Chief Technical Operations Officer (CTOO)

Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases, today announced it has closed an oversubscribed $60 million Series A financing.

Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics subsidiary towards the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020).

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the context of the developing situation with the COVID-19 pandemic.

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it has notified the U.S. Food and Drug Administration (FDA) of its intent to distribute the Company’s SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit intended for professional use, which delivers results in less than 10 minutes at the point-of-care

NovuHealth, the healthcare industry’s leading consumer engagement company, today announced a Rapid Response Engagement Solution to help health plans communicate with members quickly and effectively during times of need, such as the current global COVID-19 pandemic.